MUCPHARM PTY LTD

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety of Nebulized Combination Therapy BromAc® in COVID-19 Respiratory Disease

Phase 1

Conditions: COVID-19 Pneumonia
COVID-19
Ventilator Associated Pneumonia
COVID-19 Acute Respiratory Distress Syndrome

Interventions: Drug: Bromelains
Drug: Acetylcysteine

First Posted Date: 2022-02-28

Last Posted Date: 2022-02-28

Lead Sponsor: Mucpharm Pty Ltd

Target Recruit Count: 30

Registration Number: NCT05258682

Nebulised BromAc in Healthy Volunteers

Phase 1

Completed

Conditions: Mucus; Plug
COVID-19 Acute Respiratory Distress Syndrome
Bromelains Adverse Reaction
COVID-19 Pneumonia
Acetylcysteine Adverse Reaction

Interventions: Drug: BromAc

First Posted Date: 2022-02-02

Last Posted Date: 2022-09-15

Lead Sponsor: Mucpharm Pty Ltd

Target Recruit Count: 12

Registration Number: NCT05220605

Locations: 🇦🇺
St George Hospital, Kogarah, New South Wales, Australia

BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei

Phase 2

Conditions: Mucinous Adenocarcinoma
Pseudomyxoma Peritonei
Peritoneal Cancer
Mucinous Tumor

Interventions: Drug: Bromelain
Drug: Acetylcysteine
Procedure: Interventional radiology insertion of drain

First Posted Date: 2019-06-06

Last Posted Date: 2022-03-15

Lead Sponsor: Mucpharm Pty Ltd

Target Recruit Count: 62

Registration Number: NCT03976973

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy